Quarter Period Consolidated Statement Of Income

Delta-Fly Pharma, Inc. - Filing #7320763

Concept 2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
Quarter period consolidated statement of income
Statement of income
Selling, general and administrative expenses
Remuneration for directors (and other officers)
77,149,000 JPY
87,200,000 JPY
Taxes and dues
56,262,000 JPY
43,374,000 JPY
Operating profit (loss)
-1,403,464,000 JPY
-1,315,810,000 JPY
Non-operating income
Interest income
14,000 JPY
13,000 JPY
Non-operating income
16,000 JPY
45,000 JPY
Non-operating expenses
Non-operating expenses
23,443,000 JPY
9,995,000 JPY
Ordinary profit (loss)
-1,426,891,000 JPY
-1,325,760,000 JPY
Profit (loss) before income taxes
-1,426,891,000 JPY
-1,325,760,000 JPY
Income taxes - current
2,502,000 JPY
3,028,000 JPY
Income taxes
2,502,000 JPY
3,028,000 JPY
Profit (loss)
-1,429,393,000 JPY
-1,429,393,000 JPY
-1,429,393,000 JPY
-1,429,393,000 JPY
-1,328,788,000 JPY
-1,328,788,000 JPY
-1,328,788,000 JPY
-1,328,788,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.